UTI Healthcare Fund (Equity, Equity Sectoral-pharma)

High
20 yrs 10 monthsStarted on:28 Jun 1999
₹ 390.37 Cras on: 03 Apr 2020
Long Term Horizon
2.53%
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.

Exit Load

Scheme Documents

Similar Funds
Nippon India pharma fund
Current NAV 146.53
Return (CAGR) 18.47%
Value Research NA
TATA India Pharma & Health Care Fund
Current NAV 9.15
Return (CAGR) -2.06%
Value Research NA
SBI Healthcare Opportunities Fund
Current NAV 115.69
Return (CAGR) 13.93%
Value Research NA

Tenure

TenureReturns (CAGR)

SIP Returns

TenureReturns (CAGR)
10 YR5.62

Portfolio

Company Name% Assets
Cipla Ltd.9.15
Divi's Laboratories Ltd.7.49
Sun Pharmaceutical Inds. Ltd.6.63
Ipca Laboratories Ltd.6.28
Lupin Ltd.5.95
Dr. Reddy's Laboratories Ltd.5.83
Ajanta Pharma Ltd.5.58
Cadila Healthcare Ltd.5.53
Aurobindo Pharma Ltd.4.43
FDC Ltd.4.36

Top Sectoral Holdings

Sector Name% Assets
Healthcare97.06
FMCG1.08

Indicators

LabelValue
Portfolio turnover ratio45
Standard Deviation15.77%
Beta0.84%

V Srivatsa

Mr. Srivatsa is a B.Com (H), Chartered Accountant, CWA. and PGDM from IIM Indore.
Prior to joining UTI in 2002 he has worked with Ford, Rhodes Parks & Co., Chartered Accountants and Madras Cements Ltd.

Other Funds Managed by V Srivatsa